Drugs Generic Most Volatile: Galectin Therapeutics (NASDAQ:GALT), Aquinox Pharmaceuticals (NASDAQ:AQXP), Eagle Pharmaceuticals (NASDAQ:EGRX), Actavis plc Ordinary (NYSE:ACT)
Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that on Monday, March 31, 2014, the Company will report results from the first cohort of its Phase 1 clinical trial examining GR-MD-02 in fatty liver disease (NASH) with advanced fibrosis. Galectin Therapeutics Inc. (NASDAQ:GALT) shares after opening at $15.90 moved to $16.34 on last trade day and at the end of the day closed at $14.51. Company price to sales ratio in past twelve months was calculated as – and price to cash ratio as 25.41. Galectin Therapeutics Inc. (NASDAQ:GALT) showed a negative weekly performance of -7.87%.
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) announced on 12 march the closing of its initial public offering of 4,830,000 shares of its common stock at a public offering price of $11.00, which included 630,000 shares issued upon the exercise in full of the underwriters’ option to purchase additional shares. Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) shares advanced 5.12% in last trading session and ended the day on $12.93. AQXP return on equity ratio is recorded as 60.90% and its return on assets is -316.70%.
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), which went public last month, has as many as six candidates in its pipeline in addition to two approved products. The company, which raised more than $50 million from its initial public offering, intends to use the funds primarily to develop its pipeline. Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares moved down -5.46% in last trading session and was closed at $12.81, while trading in range of $12.56 – $14.25. Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) year to date (YTD) performance is -3.10%.
Actavis plc (NYSE:ACT) and Valeant Pharmaceuticals International, Inc. (VRX) (VRX) on 25 march announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013. Actavis plc Ordinary Shares (NYSE:ACT) weekly performance is -6.25%. On last trading day company shares ended up $202.94. Actavis plc Ordinary Shares (NYSE:ACT) distance from 50-day simple moving average (SMA50) is 0.93%. Analysts mean target price for the company is $237.27.